Roche’s Fenebrutinib Receives FDA Priority Review for Relapsing and Primary Progressive Multiple Sclerosis

RegulatoryFenebrutinibPositive

AI Analysis

Summary

Roche's Fenebrutinib has received FDA Priority Review status for the treatment of relapsing and primary progressive multiple sclerosis. This expedited review pathway indicates FDA recognition of the potential significance of the therapy.

Outcome Details

Priority Review granted

Importance:7/10

Sentiment:

0.70

FDAPriority ReviewMultiple SclerosisRegulatory

Related Companies

$RHHBY

Read the original article

Published by yahoo_finance on September 30, 2026 2:45 PM

Read Original